198 related articles for article (PubMed ID: 33066540)
1. Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity.
Patel N; Tian JH; Flores R; Jacobson K; Walker M; Portnoff A; Gueber-Xabier M; Massare MJ; Glenn G; Ellingsworth L; Smith G
Vaccines (Basel); 2020 Oct; 8(4):. PubMed ID: 33066540
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
3. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.
Palomo C; Mas V; Thom M; Vázquez M; Cano O; Terrón MC; Luque D; Taylor G; Melero JA
J Virol; 2016 Jun; 90(11):5485-5498. PubMed ID: 27009962
[TBL] [Abstract][Full Text] [Related]
4. A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes.
Swanson KA; Balabanis K; Xie Y; Aggarwal Y; Palomo C; Mas V; Metrick C; Yang H; Shaw CA; Melero JA; Dormitzer PR; Carfi A
J Virol; 2014 Oct; 88(20):11802-10. PubMed ID: 25078705
[TBL] [Abstract][Full Text] [Related]
5. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
[TBL] [Abstract][Full Text] [Related]
6. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
[TBL] [Abstract][Full Text] [Related]
7. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
9. Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B.
Joyce MG; Bao A; Chen M; Georgiev IS; Ou L; Bylund T; Druz A; Kong WP; Peng D; Rundlet EJ; Van Galen JG; Wang S; Yang Y; Zhang B; Chuang GY; McLellan JS; Graham BS; Mascola JR; Kwong PD
Pathog Immun; 2019; 4(2):294-323. PubMed ID: 31893251
[TBL] [Abstract][Full Text] [Related]
10. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus.
Boyington JC; Joyce MG; Sastry M; Stewart-Jones GB; Chen M; Kong WP; Ngwuta JO; Thomas PV; Tsybovsky Y; Yang Y; Zhang B; Chen L; Druz A; Georgiev IS; Ko K; Zhou T; Mascola JR; Graham BS; Kwong PD
PLoS One; 2016; 11(7):e0159709. PubMed ID: 27463224
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.
Ruckwardt TJ; Morabito KM; Phung E; Crank MC; Costner PJ; Holman LA; Chang LA; Hickman SP; Berkowitz NM; Gordon IJ; Yamshchikov GV; Gaudinski MR; Lin B; Bailer R; Chen M; Ortega-Villa AM; Nguyen T; Kumar A; Schwartz RM; Kueltzo LA; Stein JA; Carlton K; Gall JG; Nason MC; Mascola JR; Chen G; Graham BS;
Lancet Respir Med; 2021 Oct; 9(10):1111-1120. PubMed ID: 33864736
[TBL] [Abstract][Full Text] [Related]
13. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
14. Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.
Kwon YM; Lee Y; Kim KH; Jung YJ; Li Z; Jeeva S; Lee S; Moore ML; Kang SM
Vaccine; 2019 Oct; 37(44):6656-6664. PubMed ID: 31542260
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
16. Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine.
Che Y; Gribenko AV; Song X; Handke LD; Efferen KS; Tompkins K; Kodali S; Nunez L; Prasad AK; Phelan LM; Ammirati M; Yu X; Lees JA; Chen W; Martinez L; Roopchand V; Han S; Qiu X; DeVincenzo JP; Jansen KU; Dormitzer PR; Swanson KA
Sci Transl Med; 2023 Apr; 15(693):eade6422. PubMed ID: 37023209
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
[TBL] [Abstract][Full Text] [Related]
18. Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection.
Espeseth AS; Cejas PJ; Citron MP; Wang D; DiStefano DJ; Callahan C; Donnell GO; Galli JD; Swoyer R; Touch S; Wen Z; Antonello J; Zhang L; Flynn JA; Cox KS; Freed DC; Vora KA; Bahl K; Latham AH; Smith JS; Gindy ME; Ciaramella G; Hazuda D; Shaw CA; Bett AJ
NPJ Vaccines; 2020; 5(1):16. PubMed ID: 32128257
[TBL] [Abstract][Full Text] [Related]
19. Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses.
Stewart-Jones GBE; Gorman J; Ou L; Zhang B; Joyce MG; Yang L; Cheng C; Chuang GY; Foulds KE; Kong WP; Olia AS; Sastry M; Shen CH; Todd JP; Tsybovsky Y; Verardi R; Yang Y; Collins PL; Corti D; Lanzavecchia A; Scorpio DG; Mascola JR; Buchholz UJ; Kwong PD
Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34551978
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses.
Mukhamedova M; Wrapp D; Shen CH; Gilman MSA; Ruckwardt TJ; Schramm CA; Ault L; Chang L; Derrien-Colemyn A; Lucas SAM; Ransier A; Darko S; Phung E; Wang L; Zhang Y; Rush SA; Madan B; Stewart-Jones GBE; Costner PJ; Holman LA; Hickman SP; Berkowitz NM; Doria-Rose NA; Morabito KM; DeKosky BJ; Gaudinski MR; Chen GL; Crank MC; Misasi J; Sullivan NJ; Douek DC; Kwong PD; Graham BS; McLellan JS; Mascola JR
Immunity; 2021 Apr; 54(4):769-780.e6. PubMed ID: 33823129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
